International trial tests oral bacterial lysate to prevent infant wheeze
Researchers have detailed a multicentre randomised clinical trial protocol to test if oral bacterial lysate reduces recurrent wheezing in infants following severe bronchiolitis.
FTMQ Health, written by our newsroom0 views
Researchers have published a global clinical trial protocol in Pediatric Research to test whether an oral bacterial lysate can prevent recurrent wheezing in infants who were hospitalised for severe bronchiolitis, Bioengineer.org reported. The study is an international multicentre randomised trial designed to evaluate the preventative treatment in vulnerable infants. [1]
Severe bronchiolitis is an acute lower respiratory infection caused primarily by viral pathogens. Bioengineer.org reported that severe bronchiolitis is the most frequent reason infants are hospitalised across high-income countries. Data from clinical registries and cohorts demonstrate that infants who require inpatient care for the condition face a heightened vulnerability to recurrent respiratory complications. [1]
Clinical trials are prospective biomedical or behavioural research studies on human participants designed to evaluate specific interventions, including new treatments and established therapies that require further study. These trials generate data regarding safety, dosage, and efficacy, and they require approval from ethics committees or health authorities before research begins. [4]
In short
- A clinical trial protocol published in Pediatric Research details an international study on oral bacterial lysate for infants.
- The trial evaluates whether oral bacterial lysate reduces recurrent wheezing after hospitalisation for severe bronchiolitis.
- Severe bronchiolitis is the leading cause of infant hospitalisation in high-income countries.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]International Clinical Trial Evaluates Oral Bacterial Lysate for Preventing Infant WheezeBioengineer.org, 5d ago (the report this story comes from)
- [2]What Happens After a Clinical Cancer Trial Ends?HealthCentral, 5d ago
- [3]Aravax Announces Positive Results of Phase 2 Clinical TrialGlobeNewswire, 5d ago
Background
- [4]Clinical trial on Wikipedia
- [5]Infant swimming on Wikipedia
- [6]Limulus amebocyte lysate on Wikipedia
- [7]Severe long COVID linked to altered lung and mouth microbiomes FTMQ Health, 37d ago
- [8]Clinical trial begins in Congo to test preventive Ebola drug FTMQ Health, 44d ago
Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Trial in Mali tests azithromycin impacts on infant antimicrobial resistanceMedical Science, 4d ago
- Severe long COVID linked to altered lung and mouth microbiomesTop Stories, 37d ago
- Trial begins on focused ultrasound for schizophrenia hallucinationsMedical Science, 15d ago
- Researchers publish protocol for yoga trial in older long COVID patientsMedical Science, 6d ago
- NHS rolls out cancer blood test trial across 200 GP practicesHealth Care, 12d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality4h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial2d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.